EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Protection Induced by a Novel Circumsporozoite Protein Malaria Vaccine is Associated with the Quality of Antibody Responses

Paul M Robben, Jack N Hutter, Lei Zhu, Heather Galli, Michael A Koren, James E Moon, Dallas R Brown, Tanisha M Robinson, Elizabeth H Duncan, Arnel D Belmonte, Martha Sedegah, Ines Lakhal-Naouar, Sheila Peel, Jessica S Bolton, Wathsala Wijayalath, Lorraine Soisson, Mangala Rao, Gary R Matyas, Evelina Angov, Elke S Bergmann-Leitner, Jason A Regules, Sheetij Dutta

The Journal of Infectious Diseases · 2026-11-04

DOI: 10.1093/infdis/jiag533 ↗
AbstractBibliografische Angaben

Abstract

Abstract Background Malaria remains an intractable global health problem. We report results of a single-center, open-label Phase 1 trial of a nearly full-length soluble recombinant Plasmodium falciparum CSP (FMP013) formulated in the Army Liposome Formulation containing QS21 (ALFQ). Methods Healthy malaria-naïve adults (n=29) were enrolled into three groups. Standard (STD) group volunteers received FMP013/AFLQ (20 µg/0.5 mL) on a 0-1-2-month schedule (n=10). Delayed group (DEL) received the same dose on a 0-1-6-month schedule (n=10). Delayed Fractional Dose (DFD) volunteers (n=9), vaccinated at 0-1-6-months, received a fractional third dose (4 µg/0.1 mL). Immunized and unvaccinated control participants underwent P. falciparum-infected mosquito bite challenge three weeks after the third immunization and safety, tolerability, efficacy, and immunogenicity were analyzed. Results All regimens were well tolerated. 5 of 9 DEL (vaccine efficacy [VE], 55.6%, 95% confidence interval [CI], 21.2-86.3%; P< 0.001), 1 of 7 DFD (VE 14.3%, CI 0.0-57.9%), and 1 of 9 STD (VE 11.1%, CI 0.0-48.3%) subjects had sterile protection. Delayed blood-stage infection was observed in 3 DEL, 2 DFD and 1 STD subjects. The FMP013/ALFQ vaccine elicited C-terminal biased responses and protection in the DEL regimen was associated with higher C-terminal avidity, and junction, minor repeat epitope-specific responses. Conclusions A soluble protein CSP vaccine, akin to particle vaccines, can elicit a protective response when delivered using a potent adjuvant and an extended vaccination schedule. These data encourage further evaluation of FMP013/ALFQ efficacy and durability in the field.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →